Trial Profile
Investigation of Pharmacokinetics, Safety, and Tolerability of Vilaprisan (BAY1002670) in Subjects With Hepatic Impairment (Classified as Child-Pugh A or B) Compared to Sex, Age, and Weight-matched Healthy Subjects Following a Single Oral Dose
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 May 2019
Price :
$35
*
At a glance
- Drugs Vilaprisan (Primary)
- Indications Uterine leiomyoma
- Focus Pharmacokinetics
- Sponsors Bayer
- 12 May 2019 Results evaluating the pharmacokinetics of the selective progesterone receptor modulator vilaprisan in participants with hepatic impairment published in the British Journal of Clinical Pharmacology
- 10 Oct 2018 Results presented at the American Society for Reproductive Medicine Scientific Congress 2018
- 17 Aug 2017 Status changed from recruiting to completed.